Cargando…

β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity

Hypertrophic cardiomyopathy (HCM) affects 1 in 500 people and leads to hyper-contractility of the heart. Nearly 40 percent of HCM-causing mutations are found in human β-cardiac myosin. Previous studies looking at the effect of HCM mutations on the force, velocity and ATPase activity of the catalytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adhikari, Arjun S., Trivedi, Darshan V., Sarkar, Saswata S., Song, Dan, Kooiker, Kristina B., Bernstein, Daniel, Spudich, James A., Ruppel, Kathleen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582153/ https://www.ncbi.nlm.nih.gov/pubmed/31213605 http://dx.doi.org/10.1038/s41467-019-10555-9

Ejemplares similares

Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light
por: Trivedi, Darshan V., et al.
Publicado: (2017)

The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin
por: Sarkar, Saswata S., et al.
Publicado: (2020)

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy
por: Kawana, Masataka, et al.
Publicado: (2017)

Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state
por: Vander Roest, Alison Schroer, et al.
Publicado: (2021)

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
por: Kawana, Masataka, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function
por: Morck, Makenna M, et al.
Publicado: (2022)

Contractility parameters of human β-cardiac myosin with the hypertrophic cardiomyopathy mutation R403Q show loss of motor function
por: Nag, Suman, et al.
Publicado: (2015)

Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C
por: Stern, Joshua A., et al.
Publicado: (2023)

Moderating the Myosin Motor to Treat Hypertrophic Cardiomyopathy
por: Papp, Zoltán
Publicado: (2022)

Effects of Troponin T Cardiomyopathy Mutations on the Calcium Sensitivity of the Regulated Thin Filament and the Actomyosin Cross-Bridge Kinetics of Human β-Cardiac Myosin
por: Sommese, Ruth F., et al.
Publicado: (2013)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

Controlling load-dependent kinetics of β-cardiac myosin at the single molecule level
por: Liu, Chao, et al.
Publicado: (2018)

Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations
por: Spudich, James A.
Publicado: (2019)

The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy
por: Jacques, Adam M., et al.
Publicado: (2008)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes
por: Alamo, Lorenzo, et al.
Publicado: (2017)

Ensemble Force Changes that Result from Human Cardiac Myosin Mutations and a Small-Molecule Effector
por: Aksel, Tural, et al.
Publicado: (2015)

Getting inside the engine - myosin modulation in hypertrophic cardiomyopathy and systolic heart failure
por: Daniels, Matthew J, et al.
Publicado: (2021)

The R403Q Myosin Mutation Implicated in Familial Hypertrophic Cardiomyopathy Causes Disorder at the Actomyosin Interface
por: Volkmann, Niels, et al.
Publicado: (2007)

Prolonged cross-bridge binding triggers muscle dysfunction in a Drosophila model of myosin-based hypertrophic cardiomyopathy
por: Kronert, William A, et al.
Publicado: (2018)

Establishing disease causality for a novel gene variant in familial dilated cardiomyopathy using a functional in-vitro assay of regulated thin filaments and human cardiac myosin
por: Pan, Stephen, et al.
Publicado: (2015)

The Hypertrophic Cardiomyopathy Myosin Mutation R453C Alters ATP Binding and Hydrolysis of Human Cardiac β-Myosin
por: Bloemink, Marieke, et al.
Publicado: (2014)

To lie or not to lie: Super-relaxing with myosins
por: Nag, Suman, et al.
Publicado: (2021)

Unequal allelic expression of wild-type and mutated β-myosin in familial hypertrophic cardiomyopathy
por: Tripathi, Snigdha, et al.
Publicado: (2011)

Myosin Modulators: The New Era of Medical Therapy for Systolic Heart Failure and Hypertrophic Cardiomyopathy
por: Lekaditi, Dimitra, et al.
Publicado: (2021)

Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner
por: Singh, Rohit R., et al.
Publicado: (2021)

Harmonic force spectroscopy measures load-dependent kinetics of individual human β-cardiac myosin molecules
por: Sung, Jongmin, et al.
Publicado: (2015)

Mutation Analysis of Three Exons of Myosin-Binding Protein C3 in Patients with Hypertrophic Cardiomyopathy
por: Mobasheri, Maryam Beigom, et al.
Publicado: (2016)

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
por: Robert-Paganin, Julien, et al.
Publicado: (2018)

Myosin-binding Protein C Compound Heterozygous Variant Effect on the Phenotypic Expression of Hypertrophic Cardiomyopathy
por: Rafael, Julianny Freitas, et al.
Publicado: (2017)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
por: Toepfer, Christopher N., et al.
Publicado: (2020)

Hypertrophic and Dilated Cardiomyopathy: Four Decades of Basic Research on Muscle Lead to Potential Therapeutic Approaches to These Devastating Genetic Diseases
por: Spudich, James A.
Publicado: (2014)

Unexpectedly Low Mutation Rates in Beta-Myosin Heavy Chain and Cardiac Myosin Binding Protein Genes in Italian Patients With Hypertrophic Cardiomyopathy
por: Roncarati, Roberta, et al.
Publicado: (2011)

Cryo-EM structure of the folded-back state of human β-cardiac myosin(*)
por: Grinzato, Alessandro, et al.
Publicado: (2023)

Cryo-EM structure of the folded-back state of human β-cardiac myosin
por: Grinzato, Alessandro, et al.
Publicado: (2023)

Screening mutations in myosin binding protein C3 gene in a cohort of patients with Hypertrophic Cardiomyopathy
por: Rodríguez-García, María Isabel, et al.
Publicado: (2010)

Prevalence of cardiac myosin-binding protein C3 mutations in Maine Coon cats with hypertrophic cardiomyopathy
por: Sukumolanan, Pratch, et al.
Publicado: (2022)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nr3jm16d07bl2qvl143vi68vbs